Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Mar 08, 2021 11:21pm
127 Views
Post# 32749821

RE:RE:International women’s day

RE:RE:International women’s dayI cannot comment on any buying or selling we may have done so far this year, but I have been very clear that the deal was a disaster yet the stock remains very attractive. The odious offering just shaved off more of the upside potential than was necessary. You will have to wait until next year when we file again to know for sure but it would be odd for me to sell when I am on record as saying there remains very meaningful upside in the stock price, perhaps massive upside if the cancer phase I trial is encouraging. I As for the small decline in our holdings in 2020, you may recall it was a high intensity year on many fronts and some clients are prone to panic. Moreover, since TH share price got clobbered despite the many pieces of good news the company produced in 2020, that only helped create additional panic in the tiny percentage of our clients who struggled to keep their wits about them under some really stressful market conditions. We did not sell any shares of TH but some clients exited, leaving us with a little less TH shares than in the previous year. You may remember I suggested as much dome time ago.
1998novl wrote: They have 4,769 followers on LinkedIn. It was posted there as well. Good on the company to establish a social media strategy and to build brand awareness in addition to strengthening their digital credibility. At least they can pay for it now, an excellent bought deal in my opinion - required to invest in the business. I'll disagree with SPCEO on the latter over and over! Also guessing SPCEO (or his followers) sold more shares on the open market in January on that news, which coincides with his negativity. (It shows SPCEO holdings declined by 240,000 shares in 2020 on latest Bloomberg filings) 


<< Previous
Bullboard Posts
Next >>